All data are based on the daily closing price as of February 24, 2025
h
Hisamitsu Pharmaceutical
4530.TSE
28.48 USD
0.27
+0.96%
Overview
Last close
28.48 usd
Market cap
2.09B usd
52 week high
36.06 usd
52 week low
22.74 usd
Target price
30.11 usd
Valuation
P/E
21.782
Forward P/E
N/A
Price/Sales
2.0812
Price/Book Value
1.2023
Enterprise Value
1.33B usd
EV/Revenue
1.3238
EV/EBITDA
9.0501
Key financials
Revenue TTM
1.00B usd
Gross Profit TTM
468.86M usd
EBITDA TTM
130.26M usd
Earnings per Share
1.31 usd
Dividend
0.86 usd
Total assets
2.40B usd
Net debt
-769.29M usd
About
Hisamitsu Pharmaceutical Co., Inc. manufactures and sells pharmaceuticals in Japan. The company provides external pain-relieving drugs under the SALONPAS, NOBINOBI, SALONSIP, AIR, SALONPAS, and FEITAS; BUTENALOCK, a remedy for athlete's foot; and ALLEGRA FX, a sinus medication for allergies. It also manufactures and sells quasi-drugs and cosmetics; MOHRUS TAPE and MOHRUS PAP XR, a transdermal analgesic anti-inflammatory drug; and patches for female hormone, asthma, and overactive bladders. The company exports its products to Asia, the United States of America, and the European area. Hisamitsu Pharmaceutical Co., Inc. was founded in 1847 and is headquartered in Tosu, Japan.